Johnson & Johnson (JNJ) Stock Trades At A Discount Following Its 97% Run

Johnson & Johnson has delivered strong share gains in recent years, so the key issue now is whether the current valuation is properly backed by the cash the business is expected to generate. Recent trial updates in oncology and medtech add more moving parts to that cash flow picture, which puts extra focus on what the underlying numbers can support. Over the past 3 years, Johnson & Johnson has returned 97.2%, which puts a lot of accumulated optimism on the line if its future cash flows do...